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PEMBANGUNAN Mycobacterium bovis BACILLE CALMETTE GUERIN 
REKOMBINAN (rBCG) YANG MENGEKSPRES TERMINUS C PROTEIN 
PERMUKAAN MEROZOIT-1 19kDA (MSP-1C) DAN PROTEIN 22 kDA DARIPADA 
DOMAIN TERMINUS N ANTIGEN SERINA BERULANG 47kDA (SE22) DARI 
Plasmodium falciparum SEBAGAI CALON VAKSIN MALARIA YANG 
BERPOTENSI PADA PERINGKAT ASEKSUAL 
 
ABSTRAK 
 
Mycobacterium bovis bacille Calmette–Guerin rekombinan (rBCG) yang 
mengekspres terminus C protein permukaan merozoit-1 19kDa (MSP-1C) dan protein 
22 kDa daripada domain terminus N antigen serina berulang 47kDa (SE22) dari 
parasit P. falciparum merupakan calon vaksin malaria terhadap peringkat kitar hidup 
aseksual. Di dalam kajian ini, MSP-1C dan SE22 telah dihasilkan secara sintetik 
bersandarkan kepada kodon yang digunakan oleh mikobakteria menggunakan teknik 
yang dikenali sebagai PCR himpunan. Selain itu, MSP-1C juga telah dimutasikan di 
beberapa asid amino tertentu untuk menggalakkan penghasilan antibodi “inhibitory” 
dan bukannya antibodi “blocking” sepertimana yang telah dilaporkan sebelum ini.  
Fragmen-fragmen MSP-1C dan SE22 telah diklonkan ke dalam plasmid “shuttle” untuk 
membantu pengekspresiannya oleh BCG. Pengekspresian epitop kitar-aseksual ini 
telah dipacu oleh promoter renjatan haba 65 (hsp65) daripada M. tuberculosis dan 
peptida isyarat daripada antigen MPT63 M. tuberculosis. Pengekspresian klon-klon 
recombinan telah berjaya dikesan oleh antibodi monoklon (mAb) spesifik 
menggunakan teknik pemblotan Western; mAb spesifik SE47 terhadap SE22 dan mAb 
spesifik 12.10 dan 1E1 terhadap MSP-1C. SE22 telah bertindakbalas terhadap SE47 
mAb sementara protein “inhibitory” MSP-1C telah bertindakbalas dengan mAb 
“inhibitory” 12.10, tetapi tidak bertindakbalas terhadap mAb “blocking” 1E1. 
Seterusnya, imunisasi mencit BALB/c dengan rBCG telah menghasilkan tindak balas 
humoral yang spesifik terhadap kedua-dua epitop kitar aseksual dengan kehadiran 
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profil Th1/Th2. Sera daripada mencit yang telah diimunisasi dengan rBCG 
mengandungi IgG2a spesifik yang tinggi terhadap kedua-dua epitop menunjukkan 
tindakbalas dengan merozoit P. falciparum sebagaimana yang telah ditunjukkan di 
dalam analisis asai immunofluoresen tidak langsung (IFA). Titer antibodi spesifik 
terhadap epitop MSP-1C dan SE22 juga jelas menunjukkan hubung kait dengan tahap 
penyekatan kemasukan merozoit ke dalam sel darah merah yang telah diuji secara in 
vitro. Selain itu, tindakbalas proliferasi limfosit daripada mencit yang telah diimunisasi 
dengan rBCG terhadap MSP-1C dan SE22 juga menunjukkan tahap proliferasi yang 
lebih tinggi berbanding kumpulan mencit kontrol. Pengekspresian sitokin intraselular 
(IL-2, IL-4 and IFNγ) bagi sel-sel CD4+ dan CD8+ juga berjaya dikesan selepas 
stimulasi in vitro dengan antigen dari kedua-dua epitop. Selanjutnya, ujian kestabilan 
awal dan ujian kestabilan jangkamasa panjang bagi keadaan in vivo juga telah 
menunjukkan rBCG adalah stabil walaupun bukan merupakan plasmid “integrative”. 
Kesimpulannya, kajian ini menunjukkan bahawa pembangunan rBCG yang 
mengekspres kombinasi 2 epitop P. falciparum dari kitar aseksual telah berjaya 
menghasilkan kedua-dua imuniti humoral dan selular terhadap parasit malaria; serta 
merupakan calon vaksin malaria yang berpotensi bagi peringkat kitar aseksual.  
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DEVELOPMENT OF RECOMBINANT Mycobacterium bovis BACILLE CALMETTE 
GUERIN (rBCG) EXPRESSING THE 19 kDa C-TERMINUS OF MEROZOITE 
SURFACE PROTEIN-1 (MSP-1C) AND THE 22 kDA OF SERINE REPEAT ANTIGEN 
(SE22) OF Plasmodium falciparum AS A POTENTIAL BLOOD-STAGE MALARIAL 
VACCINE 
 
ABSTRACT 
 
Recombinant Mycobacterium bovis bacille Calmette–Guerin (rBCG) expressing 
the 19 kDa C-terminus of merozoite surface protein-1 (MSP-1C) and a 22 kDa protein 
(SE22) from the 47 kDa N-terminal domain of serine repeat antigen (SERA) of P. 
falciparum is a potential blood-stage malarial vaccine candidate. In the present study, 
the MSP-1C and SE22 were synthetically generated in favour of mycobacterium codon 
usage by assembly PCR. More importantly, the synthetic MSP-1C was mutated at 
various sites to induce the production of inhibitory but not blocking antibodies as 
previously reported. The MSP-1C and SE22 fragments were cloned into a shuttle 
plasmid to facilitate expression by BCG. The expression of the blood-stage epitopes 
were driven by the heat shock protein 65 (hsp65) promoter from M. tuberculosis and 
the signal peptide from the MPT63 M. tuberculosis antigen. Expression of the 
recombinant clones were detected by specific monoclonal antibodies using Western 
blotting; SE47 mAb against the SE22 and 12.10 and 1E1 mAbs against the MSP-1C. 
The SE22 successfully reacted with SE47 mAb while the MSP-1C protein reacted with 
the inhibitory mAb 12.10, but not the blocking mAb 1E1. The immunization of BALB/c 
mice with the rBCG elicited specific humoral responses against both blood-stage 
epitopes with a mixed Th1/Th2 profile. Immunized sera containing high levels of 
specific IgG2a against both epitopes (as determined by ELISA) were reactive with 
fixed P. falciparum merozoites as demonstrated by the indirect immunofluorescence 
assay (IFA). In addition, the antibody titres against the MSP-1C and SE22 epitopes 
appeared to correlate with the levels of inhibition of merozoite invasion of erythrocytes 
 xxii
in vitro. Furthermore, the lymphocyte proliferative response to MSP-1C and SE22 from 
rBCG-immunized mice was significantly higher than the control groups. The 
expression of intracellular cytokines (IL-2, IL-4 and IFNγ) in CD4+- and CD8+ cells were 
also detectable following in vitro stimulation with both epitopes. Preliminary and long-
term in vivo stability analyses showed that the rBCG were stable in spite of being a 
non-integrative plasmid. In conclusion, this study demonstrated that a single construct 
expressing a combination of two blood-stage epitopes of P. falciparum induced 
appropriate humoral and cellular responses against the parasites; paving the way for 
the construction of a potential blood-stage malarial vaccine.  
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Introduction 
Malaria is one of the commonest infectious diseases in the tropics. As reported in the 
World Malaria Report 2005 (WHO, 2005), at the end of 2004, 107 countries and 
territories had areas at risk of malaria transmission. Therefore, some 3.2 billion people 
live in malarious area and are highly exposed to infection. Malaria remains the greatest 
burden in Africa especially in the sub Saharan region, and also well distributed 
throughout the Eastern Mediterranean, Central Asia and South-East Asia; South and 
Central America regions (WHO, 2005). In Africa, 18% of deaths in children under 5 
years of age are due to malaria infection, and P. falciparum causes the vast majority of 
infections in this region.  Malaria is also a major cause of morbidity and mortality in 
pregnant women in endemic area (WHO, 2005). Patterns of malaria transmission and 
disease vary markedly between regions and even within individual countries. This 
diversity results from variations between malaria parasites and mosquito vectors, 
ecological conditions that affect malaria transmission and socioeconomic factors, such 
as poverty and access to effective health care and prevention services (WHO, 2005). 
Attack of this disease can be very severe and can lead to death if they remain 
undetected and untreated. Moreover, as a result of the spread of drug-resistant 
parasites and insecticide-resistant mosquitoes, there are now effectively fewer tools to 
control malaria than what existed 20 years ago (Phillips, 2001). Therefore the 
development of a vaccine against malaria has been a major agenda for controlling the 
disease.  
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1.2 History of malaria 
1.2.1 Ancient History 
The ancestors of the malaria parasites have probably existed at least half a billion 
years ago. The discovery of 30 million year old fossilized mosquitoes which probably 
originated from Africa proved that the presence of the vector for malaria disease has 
existed since ancient times. Mentions of malaria can be found in the ancient Roman, 
Chinese, Indian, Greek, Egyptian and European manuscripts and also later in 
numerous Shakespearean plays (reviewed by Carter and Mendis, 2002; Cox, 2002). 
From the Italian word “mal’aria” which means "bad or evil air", malaria has probably 
influenced to a great extent human population and human history (Sherman, 1998).  
 
The symptoms of malaria were described in ancient Chinese medical writings. In 2700 
BC, several symptoms that characterized malaria symptoms were described in the Nei 
Ching, The Canon of Medicine. This Chinese medical manuscript apparently described 
symptoms that refer to repeated paroxysmal fevers associated with enlarged spleens 
and a tendency to epidemic occurrence, suggesting P. vivax and P. malariae infections 
(reviewed by Sherman, 1998; Carter and Mendis, 2002). During ancient India, the 
Vedic (3,500 to 2,800 years ago) and Brahmanic (2,800 to 1,900 years ago) scriptures 
of Northern India also contain many references to fevers which characterized malaria 
which they referred as the King of Disease. Charaka Samhita, one of the ancient 
Indian texts on Ayurvedic medicine which was written in approximately 300 BC, and 
the Susrutha Samhita, written about 100 BC, refer to diseases where fever is the main 
symptom and associated with the bites of the insects which also characterized malaria 
disease (reviewed by Sherman, 1998; Carter and Mendis, 2002). 
 
Malaria also appeared in the writings of the Greeks from around 500 BC. Hippocrates, 
"The Father of Medicine" and probably the first malariologist described the various 
malaria fevers which infected humans by 400 BC. The Hippocratic corpus was also the 
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first document which mention about splenic change in malaria and he also claimed that 
malaria was also transmitted due to ingestion of stagnant water (reviewed by Vinetz et 
al., 1998). Malaria was also mentioned in the ancient Sumerian and Egyptian texts 
(reviewed by Sherman, 1998). The texts dating from 3,500 to 4,000 years ago also 
refer to fevers and splenomegaly, which were suggestive of malaria. The Sumerian 
records apparently made frequent reference to deadly epidemic fevers, probably due 
to P. falciparum.  
 
1.2.2 Discovery of the malaria parasite 
By early seventeenth century, the Italian physician Giovanni Maria Lancisi made some 
astounding observations on malaria. He was the first to describe the characteristic 
black pigmentation of the brain and spleen in the victims of malaria in 1716 (reviewed 
by Roncalli Amici et al., 2001). A year later in 1717, in his monograph entitled Noxious 
Emanations of Swamps and Their Cure, he echoed the old theories of Varro and 
Celsus by speculating that malaria was due to "bugs" or "worms" which entered the 
blood and revived the old idea that mosquitoes might play a role. In 1847, a German 
physician, Heinrich Meckel, identified round, ovoid, or spindle-shaped structures 
containing black pigment granules in protoplasmic masses in the blood of a patient 
with fever (reviewed by Cox, 2002). Thus Meckel probably saw the malaria parasites 
for the first time, but unfortunately he could not recognize the true importance of his 
finding. In 1848, Schutz specifically associated these pigments with malaria when he 
observed it in the internal organs of patients who had died of malaria. Later in 1849, 
Virchow demonstrated pigmented bodies in the blood of a patient who had died from 
chronic malaria. In 1850, Hischl had also confirmed the presence of pigment with 
intermittent fevers. Even with all these evidence, the black granular bodies were 
somehow never suspected to be the cause of malaria until 1879, when Afanasiev 
proposed that these bodies might be the agents of the disease (reviewed by Shuman 
1998; Cox, 2002). 
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Finally, it was Charles Louis Alphonse Laveran, a French army surgeon who was the 
first to notice parasites in the blood of a patient suffering from malaria. This occurred 
on the 6th of November 1880. He believed that the tertian, quartan, and quotidian 
malaria occurred during different stages in the parasite's development. In 1885, 
Camillo Golgi an Italian neurophysiologist, established that there were at least two 
forms of the disease, one with tertian periodicity (fever every other day) and one with 
quartan periodicity (fever every third day) (reviewed by Sherman,1998; CDC, 2004). 
He also demonstrated that the fever coincided with the rupture and release of 
merozoites into the blood stream and that the severity of symptoms correlated with the 
number of parasites in the blood. Camillo Golgi was also the first to photograph the 
pigmented quartan malaria parasite in 1890 (reviewed by Roncalli Amici, 2001). 
 
1.2.3 Nomenclature of the human malaria parasite 
The nomenclature of malaria parasites has been a matter of intense debate since the 
17th century. In 1880, Laveran had seen different forms of the malaria parasite and 
firmly believed that all of the parasites belonged to one species. He named them 
Oscillaria malariae (reviewed by Garnham, 1996). However, In 1884 Marchiafava and 
Celli called the same forms of the parasite as Plasmodium (reviewed by Roncalli 
Amici, 2001). In 1890, the Italian investigators Giovanni Batista Grassi and Raimondo 
Filetti were the first to differentiate and introduced the names Haemamoeba vivax and 
H. malariae for two of the malaria parasites (reviewed by Roncalli Amici, 2001). In 
1892, Grassi and Feletti, proposed the genus name Laverania which was zoologically 
correct, as an honor to Laveran (reviewed by Roncalli Amici, 2001). In 1897, an 
American, William H. Welch, proposed the name Haematozoon falciparum for the 
parasite with the crescent-shaped gametocytes and causes malignant tertian malaria 
(reviewed by Garnham, 1996). Confusion continued well into the 20th century over 
whether all of the parasites belonged to one species or to several. Finally, the genus 
name for the malaria parasite, Plasmodium of Marchiafava and Celli was used for all 
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species (reviewed by Roncalli Amici, 2001). The species name of the parasite 
suggested by Laveran known as malariae (Laveran, 1967), by Grassi and Feletti 
known as vivax (reviewed by Roncalli Amici, 2001) and by Welch known as falciparum 
(reviewed by Garnham, 1996). The fourth human parasite, P. ovale was finally 
identified by John William Watson Stephens in 1922 (reviewed by CDC, 2004). 
 
1.2.4 Discovery of the transmission of malaria parasite 
The connection between malaria and mosquitoes was suspected from ancient times. 
One of the oldest scripts, written several thousand years ago in cuneiform script on 
clay tablets, described the Babylonian god of destruction and pestilence, pictured as a 
double-winged, mosquito-like insect. The ancient Hindus were also conscious of the 
mosquito's harmful potential. In 800 B.C. the Indian sage Dhanvantari wrote about the 
diseases caused by bites of the mosquitoes and Susrutha Samhita also mentions 
about a possible link between fevers and insects like mosquitoes (reviewed by 
Sherman, 1998). 
 
In 1882, Albert Freeman Africanus King (1841-1915), a US Physician, proposed a 
method to eradicate malaria from Washington, DC. He suggested to encircle the city 
with a wire screen as high as the Washington Monument (reviewed by Phillips, 2001). 
His hypothesis to link mosquitoes with the malaria transmission was proven by Major 
Sir Ronald Ross. In August 20th, 1897, Ross, a British officer in the Indian Medical 
Service, was the first to demonstrate that the malaria parasites could be transmitted 
from infected patients to mosquitoes (reviewed by Mary, 1998). With his brilliant 
research, he has not only identified the habits and habitats of these mosquitoes but 
also proposed detailed plan of action to contain their breeding. His further work with 
bird malaria showed that mosquitoes could transmit malaria parasites from bird to bird. 
This necessitated a sporogonic cycle (the time interval during which the parasite 
developed in the mosquito). Thus, the problem of malaria transmission was solved.  
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1.3 Malaria distribution 
Malaria remains a major global health problem, after HIV and tuberculosis (WHO, 
2005). Malaria causes an estimated 350–500 million clinical malaria episodes 
annually, resulting in over 1 million deaths (WHO, 2005). Previously extremely 
widespread, the malaria is now confined to Africa, Asia and Latin America (Figure 1.1). 
Of these, south Saharan Africa remains the region that has the greatest burden of 
malaria cases. P. falciparum causes most of the severe disease, and is the most 
prevalent in parts of Africa, South-East Asia and the Western Pacific (see also Figure 
1.1). As reported by WHO (2005), from 60% of the worldwide malaria cases, 
approximately 75% of global falciparum malaria cases and more than 80% of malaria 
deaths occur in south Saharan Africa. The less dangerous malaria species, P. vivax 
occurs with the widest geographical range in temperate and tropical zones and is 
found in most of Asia, and in parts of the Americas, Europe and North Africa. P. 
malariae also has a similar range of distribution as P. falciparum which is more 
common in Africa and also South-East Asia and P. ovale which is predominantly found 
in Africa, is however a rare species found in South-East Asia. 
 
Malaria incidence is determined by a variety of factors, particularly the abundance of 
anopheline mosquito species, human behavior, and the presence of malaria parasites. 
Global variations in the parasite–vector–human transmission dynamics influence the 
risk of the disease and death from malaria. Malaria is more common in rural areas 
than in cities; this is in contrast to dengue fever where urban areas present the greater 
risk. For example, the cities of the Philippines, Thailand and Sri Lanka are essentially 
malaria-free, but the disease is present in many rural regions. The variation in the 
malaria burden also depends on climatic variation. 
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Figure 1.1 Global distribution of malaria transmission risk for 2003 (Adapted from World Malaria Report 2005) 
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Anthropogenic climate change may directly affect the behavior and geographical 
distribution of the malaria mosquitoes and the life cycle of the parasite, and thus 
change the incidence of the disease (Willem et al., 1995). The increase of malaria 
incidence in the tropics is due to the best combination of adequate rainfall, 
temperature and humidity, which play crucial roles in malaria epidemiology because it 
allows breeding and survival of the mosquitoes. Different levels of socioeconomic 
development are also an important factor that determines variation in malaria 
distribution. General poverty, quality of housing and access to health care and health 
education, as well as the existence of active malaria control programmes, all strongly 
influence the geographic location of the disease. The poorest nations generally have 
the least resources for adequate control efforts. For example, malaria in West Africa, 
Ghana and Nigeria is present throughout the entire country due to a poor sanitary and 
housing development and also lack of education and resources for control and 
elimination efforts (WHO, 2005).  
 
1.3.1 Malaria in Malaysia 
Malaria infection in Malaysia is mainly caused by P. vivax infection followed by P. 
falciparum or mixed infection as reported for the year of 2003 (Figure 1.2 (A)) (WHO, 
2005). The malaria cases reported in Malaysia as divided by age and gender for the 
year 2000 to 2003 is indicated in Figure 1.2 (B). The incidence of malaria by selected 
sub-national area from 2000-2003 is also shown in Figure 1.2 (C). Non-peninsular 
region (Sabah and Sarawak) mainly contributed to the major malaria cases in Malaysia 
followed by Pahang, Perak and Johor. Most of the cases implicated are primarily in the 
aboriginal Orang Asli population which is mainly distributed at the centre of Peninsular 
Malaysia.  
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Figure 1.2 Malaria cases in Malaysia from 2000-2003 (Adapted from WHO Malaria 
Report 2005). 
 
(A) Malaria infection in Malaysia as classified by type and quality for 2003; (B) Malaria 
cases in Malaysia divided by age and gender and (C) reported malaria cases by 
selected sub-national area for 2000 to 2003 as reported by Ministry of Health 
Malaysia.  
 
15 of 15 areas  2000 2001 2001 2003 % 
Sarawak  3011 3145 2496 2615 41 
Sabah    5776 6050 5096 1770 28 
Pahang   1301 1544 1563   850 13 
Johor      710   671   579   284   4 
Perak      852   470   280   276   4 
Selangor     271   172   159   119   2 
Pulau Pinang    209   197     76   106   2 
Kelantan     386   184   333     99   2 
Kedah        12     26     82     92   1 
Terengganu       94     76   140     47   1 
Negeri Sembilan     37    205   180         45   1 
W. P. Kuala Lumpur     27      20     15     20     <1 
W. P. Labuan           7     <1 
Melaka                    18      15     16       7 <1 
Perlis         1            5          4           1 <1 
 
 
 
 
 
 
Probable or clinically diagnosed 
 Malaria cases 
Severe (inpatient or hospitalized) cases 
Malaria deaths 
 
Slides taken 
Rapid diagnostic tests (RDTs) taken 
 
Laboratory confirmed 
 Malaria cases   6338 
 P. falciparum or mixed  2884 
 P. vivax    3127 
 Severe (inpatient or  
 hospitalized cases)    421 
 Malaria deaths       21 
 
Investigations  
 Imported cases       861 
 
Estimated reporting completeness (%) 100          
Reported malaria cases  6338
Reported malaria deaths     21 
 
Group Subgroup    2000    2001  2002    2003          % 
 Total      12705  12780  11019   6338 100 
Gender Male       8633     8817   7527   4483   71 
 Female       4072     3963   3492   1855   29 
Age  <5 years       1795     1723   1486  607   10 
 >5 years     10910   11057   9533 5731   90 
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1.4 The mosquito vector  
Human malaria is transmitted by female mosquitoes of the genus Anopheles. Of 
approximately 430 Anopheles species, about 50 transmit malaria in nature, depending 
on the region and the environment (Subbarao and Sharma, 1997; Riehle et al., 2006) 
(see Figure 1.3). Anophelines that can transmit malaria are not only found in malaria-
endemic areas, but also in areas where malaria has been eliminated. Thus, the latter 
areas are constantly at risk of re-introduction of the disease. Apart from malaria, 
anopheles mosquitoes are also known to transmit W. bancrofti (filarial worm); the 
Timorese filaria, Brugia timori; several arboviruses including eastern and western 
equine encephalitis, Venezuelan equine encephalitis etc. 
 
The anopheline mosquito has four distinct stages in its life cycle; egg, larva, pupa, and 
adult (Figure 1.4).  The adult is an active flying insect, while the other stages occur in 
water.  The female Anopheles is infected by the malaria parasite during its blood meal 
of infected patients. Once ingested, malaria parasites must undergo development 
within the Anopheline mosquito before they become infectious to humans. The time 
required for development in the mosquito which is called the extrinsic incubation period 
ranges from 10-21 days, depending on the parasite species and the temperature. If a 
mosquito does not survive longer than the extrinsic incubation period, then it will not be 
able to transmit any malaria parasites. The length of the life cycle completes within a 
week depending on the temperature and species characteristics.  However, it is not 
possible to measure directly the life span of mosquitoes in nature. Charlwood et al., 
(1997) reported that indirect estimates of daily survivorship of An. gambiae in Tanzania 
ranged from 0.77 to 0.84 meaning that at the end of one day between 77% and 84% 
will survive. 
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Figure 1.3 Global distribution of malaria vectors (adapted from World Malaria Report, 2005). 
 
 12
 
 
 
 
 
 
Anopheles Egg 
 
 
  Anopheles Adult       Anopheles Larva 
 
 
 
Anopheles Pupa 
 
 
Figure 1.4 The life cycle of Anopheles mosquito (adapted and modified 
from CDC, 2004) 
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Phillips (2001) reported that there are three very efficient malaria vectors in the world 
An. gambiae, An. arabiensis and An. funestus. However, An. gambiae is the most 
common vector of falciparum malaria in Africa (Mbogo et al., 1995, Mendis et al., 
2000), and is also one of the most difficult to control. An. gambiae is anthropophilic 
and usually transmits P. falciparum parasite (Amorosa et al., 2005). However, there 
are several other principal malaria vectors in the Asian region such as An. culicifacies, 
An. minimus, An. annularis, An. dirus, An. fluviatilis, An. maculipennis, An. sacharovi, 
An. superpictus, An. farauti (WHO, 2005) and An. maculatus which is the main vector 
for malaria transmission in Peninsular Malaysia (Singh and Tham, 1988; Rahman et 
al., 2002).   
 
1.5 The parasite 
Malaria is caused by a one-celled parasite from the genus Plasmodium. Plasmodium 
species are apicomplexa and exhibit a heteroxenous life cycle involving a vertebrate 
host and an arthropod vector. More than 100 different species of Plasmodium exist, 
and they produce malaria in many types of animals and birds, as well as in humans. 
However, there are 4 common species that infect humans; P. falciparum, P. malariae, 
P. vivax and P. ovale.  Recently P. knowlesi has also been suggested to infect humans 
(Singh et al., 2004). Each species has a distinctive microscopic appearance, differs in 
their life cycles and each one produces a different set of clinical manifestation (Figure 
1.5). Two or more species can live in the same area and can infect a single individual 
at the same time. Of these, P. falciparum is the most widespread and is the main 
cause of malarial morbidity and mortality (WHO, 2002). The infection can develop 
suddenly and produce several life-threatening complications. P. vivax, P. malariae and 
P. ovale can also cause febrile illness but are rarely fatal. P. malariae infections not 
only produce typical malaria symptoms but they also can persist in the blood for very 
long periods, possibly decades, without ever producing symptoms (Vinetz et al., 1998). 
A person with asymptomatic P. malariae infection however, can infect others, 
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Figure 1.5 Blood stages of Plasmodium (A) P. falciparum and (B) P. vivax 
(adapted from Davis, 2003). 
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              (C)                    (D) 
                   
             (E) 
 
Figure 1.5 Blood stages of Plasmodium (C) P. malariae, (D) P. ovale (adapted from Davis, 2003) and P. knowlesi (adapted from Singh et 
al., 2004).
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either through blood donation (Hang et al., 1995)  or mosquito bites. P. ovale is rare; 
however it can cause relapses. Besides the four human species of Plasmodium that 
commonly cause malaria in humans, the simian malaria parasite P. knowlesi can also 
cause malaria in humans (Garnham, 1996). As reported by Singh et al. (2004), human 
P. knowlesi infections that previously misdiagnosed by microscopy mainly as P. 
malariae have recently triggered a large number of cases in Kapit, Sarawak. The P. 
knowlesi infection in human has caused various clinical manifestations, varying from 
moderate to severe; but it is treatable with anti-malarial treatment (Singh et al., 2004). 
 
1.5.1 Life cycle of human malaria parasite 
The life cycle of human malaria parasite is complex because it requires both human as 
well as the mosquito host (Phillips, 1983) (Figure 1.6). In general, Plasmodium spp. 
reproduces sexually in Anopheles mosquitoes. However in humans, the parasite 
reproduces asexually in liver cells prior to being reproduced repeatedly in RBCs. The 
sporozoite (approximately 100) in the saliva of an infected female Anopheles mosquito 
is transmitted into the human blood stream during its blood meal (Rosenberg et al., 
1990). Within 30 to 45 minutes, the thread-like sporozoites invade hepatocytes though 
the actual mechanism of invasion remains unclear (Phillips, 2001). Growth and division 
of the human parasites in the liver take approximately 6 to 15 days depending on the 
Plasmodium species; approximately 6, 10 and 15 days for P. falciparum, P. vivax and 
P. ovale and P. malariae, respectively (Phillips, 2001; Moore et al., 2002; Hisaeda et 
al., 2005). Alternatively, some P. vivax and P. ovale sporozoites turn into hypnozoites, 
a form that can remain dormant in the liver for months or years until they are 
reactivated to complete the pre-erythrocytic cycle with the release of merozoites into 
the bloodstream to precipitate a relapse infection (Phillips, 2001; Hisaeda et al., 2004). 
At the end of the cycle, thousands of merozoites are released into the bloodstream 
flowing through the sinusoids, and within 15 to 20 seconds, the merozoites attach to  
 
 17
 
 
 
 
 
Figure 1.6 Life cycle of the malaria parasite. The life cycle commences with the 
inoculation of sporozoites that travel to the liver (1). After a period in the liver, once 
parasites multiply intracellularly, merozoites rupture from infected hepatocytes and 
invade RBCs (2). The merozoites invade RBC, continue it life cycle within RBC (3) or 
develop into nonmultiplying sexual forms (4). Sexual forms (gametocytes) are taken up 
by the mosquito (5). These emerge in the gut of the mosquito as gametes, which fuse 
to form a zygote, then and oocyst, and sporozoite develop, which travel to the salivary 
galand (6). (adapted from Nature Reviews Immunology, 2001). 
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and invade RBCs where they fuel their activities by consuming haemoglobin (Phillips, 
2001; Moore et al., 2002). The schematic depiction of stages in RBC invasion by the 
malaria merozoite is shown in Figure 1.7. 
 
In the RBCs, most merozoites go through another cycle of asexual reproduction, again 
forming schizonts filled with yet more merozoites. When the schizont matures, the 
RBC ruptures and merozoites burst out. Normally for human malaria parasites, one 
complete asexual cycle takes approximately 48 or 72 hours, depending on the species 
(Phillips, 2001 and Moore et al. 2002). The newly released merozoites invade other 
RBCs, and the parasite continues its cycle until it is controlled by the immune 
response or anti-malarial drug or chemotherapy. All symptoms commence when the 
parasites undergo this asexual stage (Hajime et al., 2005). At this stage, it will reach a 
sufficient level to generate the host’s pathogenic process. Fever, a hallmark of malaria, 
is due to parasite-derived molecules, which are released from ruptured host cells by 
activating the inflammatory cells such as macrophages (Hajime et al., 2005). These 
secreted pro-inflammatory cytokines include powerful endogenous pyrogens, such as 
interleukin (IL)-1 and tumor necrosis factor (TNF-α). Typically, P. vivax takes 48 hours 
(tertian malaria) and P. malariae takes 72 hours (quartan malaria) to undergo a 
complete cycle in RBCs. The Plasmodium parasite is able to complete its life cycle in 
the mosquito because some of the merozoites that penetrate RBCs do not develop 
asexually into schizonts. Eventually, some merozoites differentiate into sexual forms 
known as gametocytes (Phillips, 2001 and Moore et al. 2002). The gametocytes 
circulate in the host’s bloodstream, awaiting a blood meal of a female Anopheles. 
Once in the mosquito’s gut, the gametocytes develop into mature male and female 
gametes. Fertilization produces an oocyst filled with infectious sporozoites. When the 
oocyst matures, it ruptures and the sporozoites migrate, by the thousands, to the 
mosquito’s salivary glands. And the cycle starts all over again when it bites her next 
victim. 
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Figure 1.7 A model of RBC invasion by the malaria merozoite (adapted from 
www.nimr.mrc.ac.uk/parasitol/blackman/rhomboid) 
 
A schematic depiction of stages in RBC invasion by the malaria merozoite. The 
parasite binds (A), reorientates until its apical end contacts the host cell surface (B), 
then enters into a parasitophorous vacuole (C). As it enters, proteins are released from 
apical organelles (D) and parasite surface proteins are shed by proteases (E). The 
entire process is complete within about 30 seconds. 
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1.6 Pathophysiology 
1.6.1 Clinical features and pathogenesis of malaria 
Much of the pathology of malaria commence when the parasites undergo the asexual 
blood cycle (Phillips, 2001). Fever due to P. falciparum, a hallmark of malaria, occurs 
initially at 48 h intervals and lasts for a few hours. Fever, normally accompanied by 
nausea, headache and chills is due to parasite-derived molecules which are released 
from ruptured host cells activating inflammatory cells such as macrophages and 
fibroblasts. These also secrete pro-inflammatory cytokines including the powerful 
endogenous pyrogens, such as IL-1 and TNFα (Angulo and Fresno, 2002). As 
reported by Kwiatkowski et al. (1993), Gambian children infected with P. falciparum 
showed reduced fever in a presence of anti-TNFα. Clinical complications of P. 
falciparum malaria occur particularly in non-immune adults and children who remain 
untreated for several days after the onset of fever. However, the most serious, and 
frequently fatal, complication is cerebral malaria. In severe cases this is associated 
with deep coma and generalised convulsions. Obstruction of cerebral venules and 
capillaries with trophozoites and schizonts is a characteristic of histopathological 
findings in cerebral malaria. However, untreated cases of acute falciparum malaria will 
cause several other common clinical complications such as severe liver failure, 
circulatory collapse, acidosis, hypoglycaemia, anaemia, hyperpyrexia, acute 
pulmonary oedema and renal failure. Despite all the complication, falciparum malaria 
is also a major cause of maternal death, abortion, stillbirth, premature delivery and low 
birth-weight in endemic areas. A study related to malaria cases in pregnant women 
showed that the placenta is identified as a preferred site for sequestration of infected 
RBCs and a sub-population of the mature forms of P. falciparum that adhere to 
chondroitin sulphate A which can be found in infected placenta (Aikawa et al., 1990, 
Bulmer et al., 1993, Fried and Duffy, 1996). Adherence of P. falciparum-infected 
erythrocytes to the endothelium of post-capillary venules assists the parasite in 
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avoiding splenic clearance and promotes sequestration in the placenta as well as the 
brain, thus promoting severe malaria infection.   
 
Some individuals have genetic resistance to malaria.  In individuals who are 
heterozygous for sickle-cell hemoglobin, the internal environment of the RBCs does 
not allow for the development of the merozoites (Wakelin, 1996).  Therefore RBCs do 
not rupture, thus limiting transmission because more merozoites are not created in the 
RBCs.  This person, although infected with malaria, does not suffer from its symptoms 
nor can the disease be spread from this person.  The Duffy antigen, which is 
expressed on the surface of the RBC, is necessary for P. vivax to enter the RBC and 
therefore people without this antigen are protected from vivax malaria.   
 
The fact that many people in endemic areas are infected with the parasite but do not 
have the disease gives evidence to the existence of acquired immunity (Wakelin, 
1996; Eisenhut, 2007).  Much research is being conducted currently into the 
mechanisms of this acquired immunity to malaria in order to create a malaria vaccine.  
It is this acquired immunity to malaria that limits the correlation between rates of 
morbidity and mortality, and malaria transmission rates (Brewster, 1999).  
 
1.6.2 Immunity to malaria 
Considerable evidence has revealed that antibodies and T cells play crucial roles in 
the protective immunity against malaria parasites (Good, 1998; Kaslow and Miller, 
1998). Since the malarial parasite infects different targets and undergoes various 
stages in its life cycle, immunity against the infection is also stage specific. Some 
studies have revealed that monocytes, macrophages, NK cells and neutrophils appear 
to play a role in innate immunity in the early stages of malarial infection (as reported by 
CDC, 2004). At the initial phase of malaria infection, Th1 immunity will play an 
important role in clearing the parasite (Langhorne et al., 1998; Angulo and Fresno, 
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2002). However later in the infection, after the initial reduction in parasitemia, there is a 
switch to a Th2-like response which is associated with the production of IL-4 and IL-10 
and the provision of help to B cells for antibody responses (Jason et al., 2001; Taylor 
et al., 2001). At this stage, B cells are necessary for the control and clearance of 
residual parasites (Langhorne et al., 1998; Holder, 1999), suggesting a requirement for 
antibody in the resolution of infection. Antibodies can mediate their protective effect by 
multiple mechanisms during the malaria infection - antibodies can neutralize the 
parasites, retard parasite development, prevent them from entering target cells and 
assist macrophages to efficiently engulf the parasites and infected cells (CDC, 2004). 
 
Previous studies have reported that antibodies, CD4+ and CD8+ αβ T cells, and γδ T 
cells have all been shown to contribute to the elimination of pre-erythrocytic parasites 
in irradiated-sporozoite-immunized mice following a sporozoite challenge (Good and 
Doolan, 1999; McKenna et al., 2000; Plebanski and Hill, 2000) and it is normally CD8+ 
αβ T cells that are required for protective immunity during this stage (Rzepczyk et al., 
1997). In addition, Kupffer cells, resident macrophages of the liver phagocytose 
sporozoites and may present parasite antigens via MHC class-I (Aidoo and 
Udhayakumar, 2000). The infected hepatocytes or Kupffer cells expressing processed 
pre-erythrocytic antigens recognized by malaria-specific CD8+ T cells; resulting in 
either inhibition of the intracellular parasite or lysis of the target cell. CD8+ T cells 
eliminate intracellular pathogens by a perforin mediated pathway in which the infected 
cell is lysed via a FAS-mediated pathway and the target cells are induced to self-
destruct (Esser et al., 1996; Aidoo and Udhayakumar, 2000) or by a cytokine (mainly 
IFN-γ)-dependent pathway in which the infected cell is stimulated to kill intracellular 
pathogens (Lalvani et al., 1997; Lenkers et al., 1997; Good and Doolan, 1999). 
Previous studies have shown that immunization with radiation-attenuated sporozoites 
induces sterile protection in animal models which is mediated predominantly by CD8+ T 
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cells and IFN-γ and directed against the intrahepatocytic stage of the parasite 
(Benmohamed et al., 1997; Winkler et al., 1998; Meraldi et al., 2005). IFN-γ-mediated 
liver stage protection is also mediated by CD4+ T cells (Charoenvit et al., 1999; Good, 
1999; Tsuji and Zavala, 2003), NK cells (Gonzalez-Aseguinolaza et al., 2000; 
Gonzalez-Aseguinolaza et al., 2002) and γδ T cells (Rzepczyk et al., 1997; McKenna 
et al., 2000). Previous studies showed that the human RTS,S vaccine  induced high 
levels of IFN-γ-secreting CS-specific CD4+ T cells and is protective in naïve volunteers 
(Stoute et al., 1997 and Lalvani et al., 1999). The presence of NK cells will also 
activate the production of IFN-γ and activates macrophages initiating them to eliminate 
infected RBCs by phagocytosis. Besides cell-mediated immunity, antibody responses 
are also elicited against sporozoites inhibiting their invasion of hepatocytes. If the 
release of merozoites from the liver into the bloodstream is prevented, the infection 
could be terminated before disease onset.  
 
Antibodies to diverse parasite antigens expressed on the surface of infected red cells, 
or on free merozoites play an important role in immunity against the asexual 
erythrocytic stage of malaria infection (Nwuba et al., 2002; Garraud et al., 2003; Okech 
et al., 2004). The antibodies can inhibit parasite growth by blocking red cell invasion by 
causing complement-mediated lysis of infected red cells and by enhancing uptake 
through Fc receptors and/or complement receptors on phagocytes (Good et al., 1998; 
Miller et al., 1998; Rotman et al., 1998; Saul et al., 1999). Although blood-stage 
protection is substantially mediated by antibodies, other protective mechanisms are 
also involved, including innate immunity, IFN-γ production and T-cells (Plebanski et al., 
2000). Furthermore, IFN-γ could also promote activation of macrophages to enhance 
clearance of infected RBCs. As reported by Luty et al. (1999), IFN-γ produced by CD4+ 
T cells to specific blood-stage antigens has been shown to be associated with 
protection against re-infection in African children. In murine malaria, IFN-γ-secreting T 
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cell clones can protect by a nitrate-dependent mechanism possibly mediated by 
macrophages and neutrophils (Jacobs et al., 1995; Stevenson et al., 1995; Matsumoto 
et al., 2001). CD4+ T-cell secretion of IFN-γ might also help induced cytophilic IgG 
blood-stage-specific antibodies and assists clearance of infected RBCs (Bouharoun et 
al., 1995; Matsumoto et al., 2001). Therefore, immune responses to blood-stage 
parasites contribute to reduction in disease severity by eradicating the parasites and 
by preventing pathogenesis.  
 
1.7 Diagnosis of malaria 
Simple light microscopic examination of Giemsa stained blood films is the most widely 
practiced and useful method for definitive malaria diagnosis and still remains the ‘gold 
standard’ for the detection and species identification of malarial parasites (WHO, 
2000). Two types of blood films are traditionally used for microscopic examination; thin 
films and thick films. Thin films are similar to usual blood films and allow the 
microscopist to speciate malaria. Meanwhile, thick films allow the microscopist to 
screen a larger volume of blood, so as to pick up low levels of infection. Advantages 
using this technique include differentiation between species, characterization of 
circulating stage, quantification of the parasite density, and ability to distinguish 
clinically important asexual parasite stages from gametocytes which may persist 
without causing symptoms. These advantages can be critical for proper case-
management and evaluating parasitological response to treatment. It is comparatively 
inexpensive. Specific disadvantages are that slide collection, staining, and reading can 
be time-consuming and technically challenging – thus microscopists need to be trained 
and supervised to ensure consistent reliability (Moody et al., 2002; Suh et al., 2004). 
 
A second method is a modification of light microscopy called the quantitative buffy coat 
(QBC) method. This technique was originally developed to screen large numbers of 
specimens for complete blood cell counts. The technique uses microhaematocrit tubes 
